Several studies suggest that MTX administrations in RA patients favors shift from expression Th1 cytokines to Th2-cytokines, as seen by decreased IFN-γ, IL-12R, CXCR3 and increased IL-10 [205,206,207,208]. Here, IL10 is linked to rheumatoid arthritis.